| Identification | Back Directory | [Name]
ETC-159 | [CAS]
1638250-96-0 | [Synonyms]
ETC-159
CS-1584
ETC1922159
ETC-1922159
ETC 1922159
ETC 159;ETC159;ETC 1922159;ETC-1922159;ETC1922159
ETC-159;ETC 159;ETC159;ETC 1922159;ETC-1922159;ETC1922159
2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide
1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)-7H-purine-7-acetamide
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)- | [Molecular Formula]
C19H17N7O3 | [MOL File]
1638250-96-0.mol | [Molecular Weight]
391.38 |
| Chemical Properties | Back Directory | [density ]
1.47±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 33 mg/ml; DMSO: 33 mg/ml; DMSO:PBS (pH 7.2) (1:7): 0.12 mg/ml | [form ]
A crystalline solid | [pka]
11.28±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)-7H-purine-7-acetamide is a novel potent PORCN inhibitor that blocks the secretion and activity of all Wnts. | [in vivo]
ETC-159 inhibits mouse PORCN with an IC50 of 18.1 nM, whereas the IC50 for Xenopus Porcn is approximately four fold higher (70 nM). ETC-159 is remarkably effective in treating RSPO-translocation bearing colorectal cancer (CRC) patient-derived xenografts. ETC-159 exhibits good oral pharmacokinetics in mice allowing preclinical evaluation via oral administration. After a single oral dose of 5 mg/kg, ETC-159 is rapidly absorbed into the blood with a Tmax of ~0.5 h and oral bioavailability of 100%[1]. | [storage]
Store at -20°C |
|
| Company Name: |
D&C Chemicals
|
| Tel: |
+86-21-58447131 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList16963/0.htm |
|